Simponi Injection, Solution
Product Images NDC 57894-070

Product Visual Gallery

This gallery contains 45 technical images submitted to the FDA as part of the official labeling for Simponi (NDC 57894-070). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Janssen Biotech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Simponi 01)

A line graph comparing Percent ACR 20 Responders over Time (Weeks) between two groups: Placebo + MTX and SIMPONI 50 mg + MTX. The vertical axis shows percent responders from 0 to 70%, and the horizontal axis shows time from 0 to 24 weeks. The graph depicts that the SIMPONI 50 mg + MTX group consistently has higher response rates compared to the Placebo + MTX group.*

FDA Label Image

Figure 2 (Simponi 02)

A line graph depicting the percentage of ACR 20 responders over time in weeks. The graph compares placebo and SIMPONI 50 mg groups, with SIMPONI showing higher response rates consistently from week 4 to week 24.*

FDA Label Image

Figure 3 (Simponi 03)

A line graph showing the percentage of ASAS 20 responders over time in weeks, comparing SIMPONI 50 mg (black squares) with placebo (open circles). The y-axis indicates percent responders, and the x-axis shows time from 0 to 24 weeks.*

FDA Label Image

Thermometer (Simponi 04)

FDA Label Image

Phone (Simponi 05)

FDA Label Image

Figure (Simponi 06)

Illustration of the Simponi (golimumab) SmartJect autoinjector showing labeled parts including cap, security seal on the cap, green safety sleeve, clear cover, thin hidden needle, viewing window, raised button area to press for injection, and expiration date location on the back.*

FDA Label Image

Figure (Simponi 07)

An illustration showing an opened box with an arrow pointing down to a prefilled injection pen, accompanied by a clock icon displaying 30 minutes. It likely indicates preparation or waiting time before using the Simponi injection pen.*

FDA Label Image

Figure (Simponi 08)

An instructional illustration showing a syringe with an expiration date label and a security seal. The image also includes a clock icon indicating 30 minutes, likely representing a time-related instruction associated with the syringe.*

FDA Label Image

Figure (Simponi 09)

Illustration showing a close-up of a device with a timer set to 30 minutes, likely indicating a waiting or treatment duration related to the product Simponi (golimumab) injection.*

FDA Label Image

Figure (Simponi 10)

An instructional illustration showing placement sites for Simponi (golimumab) subcutaneous injection patches or adhesive bandages on the upper arm, abdomen, and thigh areas.*

FDA Label Image

Figure (Simponi 11)

An instructional illustration showing hands using an alcohol swab to clean an injection site on the skin in preparation for subcutaneous injection.*

FDA Label Image

Figure (Simponi 12)

An instructional illustration showing how to unlock and separate parts of a Simponi autoinjector pen device. The top half depicts twisting the cap to unlock, and the bottom half shows pulling the cap off to prepare the device for use.*

FDA Label Image

Figure (Simponi 13)

Instructional illustration showing a hand holding a Simponi autoinjector pen for subcutaneous injection, with a close-up detail of the green safety sleeve at the needle end.*

FDA Label Image

Figure (Simponi 14)

An instructional illustration showing the correct technique for subcutaneous injection using a prefilled pen device. The image depicts a hand pressing the injection pen vertically down onto the skin, with a zoomed inset highlighting the pen's tip position on the skin surface.*

FDA Label Image

Figure (Simponi 15)

FDA Label Image

Figure (Simponi 16)

An instructional illustration showing a hand holding an injection pen with a finger pressing the button at the bottom, accompanied by text saying "1st CLICK!" indicating the first step in using the device.*

FDA Label Image

Figure (Simponi 17)

An instructional illustration showing a hand pressing on an injection pen device, with the text '2nd CLICK!' indicating the step for administering the injection. The pen has a small window displaying a yellow indicator.*

FDA Label Image

Figure (Simponi 18)

An illustration showing a close-up view of an injection device tip with a colored internal component, likely representing part of the mechanism for a subcutaneous injection. This image relates to the administration of Simponi (golimumab) injection solution.*

FDA Label Image

Figure (Simponi 19)

Illustration showing a hand holding a prefilled autoinjector pen with a yellow label applied near its front end. The pen is being positioned to dispose of its needle into a red sharps container marked with a biohazard symbol on the white lid. The sharps container includes a small receptacle opening for safe disposal of used needles and syringes.*

FDA Label Image

Figure (Simponi 20)

An instructional illustration depicting a hand holding a cotton ball or gauze pad pressing on a skin surface, likely demonstrating proper post-injection care.*

FDA Label Image

Figure (Simponi 21)

Illustration showing the use of a prefilled injection device being administered subcutaneously into the skin of a person's arm or leg. The injection device is held firmly in one hand while the needle is inserted at the injection site.*

FDA Label Image

Image (Simponi 22)

Simponi 100 mg/mL or 50 mg/0.5 mL subcutaneous injection syringe device shown without outer packaging. The image displays a prefilled syringe with an attached needle, designed for administering golimumab solution by subcutaneous injection. The syringe body is transparent with dosage markings and a plunger for delivering the medication, manufactured by Janssen Biotech, Inc.*

FDA Label Image

Image (Simponi 22a)

Simponi single-dose prefilled syringe label displaying the proprietary name Simponi with the dosage strength of 50 mg/0.5 mL in injection solution form for subcutaneous use. The label also shows the Janssen Biotech, Inc. logo.*

FDA Label Image

Image (Simponi 23)

FDA Label Image

Image (Simponi 24)

An instructional diagram of a prefilled syringe for Simponi (golimumab) injection, showing labeled parts including plunger, safety guard, finger flange, body with viewing window, and needle cover, with warnings not to hold or pull the plunger and not to remove the needle cover until ready to inject.*

FDA Label Image

Image (Simponi 24a)

An instructional diagram of a prefilled syringe mechanism for Simponi (golimumab) injection. The image labels the syringe components showing the plunger locks, safety guard activation, and needle retraction into the body to illustrate the safety features of the device.*

FDA Label Image

Image (Simponi 25)

Instructional figure titled '1. Prepare for your injection' showing a step in the process of preparing an injection, with a blue header bar emphasizing the step number and title, designed for patient guidance on proper injection technique.*

FDA Label Image

Image (Simponi 25a)

An instructional illustration showing a 30-minute timer beside a rectangular medication box, indicating a recommended time duration, likely related to Simponi injection preparation or storage instructions.*

FDA Label Image

Image (Simponi 25b)

Illustration showing common injection sites for subcutaneous administration of Simponi (golimumab) injection solution, highlighting the upper thigh, abdomen, and upper arm areas.*

FDA Label Image

Image (Simponi 26)

An instructional diagram showing two hands: one hand is washing with water droplets falling onto it, and the other hand is using a cloth or wipe on a surface. The illustration likely demonstrates proper hygiene or cleaning technique before product use.*

FDA Label Image

Image (Simponi 27)

An instructional diagram illustrating a close-up view of a finger operating a device, possibly showing the step of pressing or holding a part of a syringe or injection pen, relevant to the subcutaneous injection process for Simponi (golimumab).*

FDA Label Image

Image (Simponi 28)

An instructional diagram labeled '2. Inject SIMPONI using prefilled syringe' displayed in a blue rectangular box with white text, indicating a step in the administration process of Simponi injection.*

FDA Label Image

Image (Simponi 29)

An instructional illustration showing the use of a syringe with a needle, depicting a drop of liquid emerging from the needle's tip, held by a hand. This image likely relates to the subcutaneous injection process for the medication Simponi (golimumab) injection solution.*

FDA Label Image

Image (Simponi 30)

An illustration showing the proper injection angle of 45 degrees for administering a subcutaneous injection. The image depicts a hand holding a syringe at this angle, preparing to inject into the skin of a forearm or thigh.*

FDA Label Image

Image (Simponi 30a)

An instructional illustration showing hands using a syringe with a safety mechanism. One hand is pulling a protective shield from the syringe needle, demonstrating preparation for a subcutaneous injection.*

FDA Label Image

Image (Simponi 30b)

An instructional illustration showing a step to remove or insert a cap on a prefilled syringe, indicated by a blue arrow. The image depicts hands holding the syringe and manipulating the cap, relevant for subcutaneous injection preparation.*

FDA Label Image

Image (Simponi 30c)

An instructional diagram showing hands preparing a syringe injection with an arrow indicating the direction to pull or push, related to subcutaneous injection technique.*

FDA Label Image

Image (Simponi 31)

Text panel titled '3. After your injection' provides instructions or information related to post-injection care or steps to follow after administering the injection. The content is from patient information or medication guide.*

FDA Label Image

Image (Simponi 32)

An instructional illustration showing a hand holding a prefilled syringe being disposed of into a biohazard sharps container, indicating safe disposal of injection materials.*

FDA Label Image

Image (Simponi 33)

An instructional illustration showing a hand applying a cotton ball or pad to a skin area, likely demonstrating the preparation or post-injection care process for a subcutaneous injection.*

FDA Label Image

Image (Simponi 33a)

FDA Label Image

Principal Display Panel (50 mg/0.5 mL Syringe Carton)

Packaging label for Simponi (golimumab) injection, solution, 50 mg/0.5 mL in a single-dose prefilled syringe. The label is produced by Janssen Biotech, Inc. and includes details about subcutaneous administration, NDC 57894-070-01, and storage instructions. The design features the Simponi logo and emphasizes the single-dose prefilled syringe format.*

FDA Label Image

Principal Display Panel (100 mg/mL Syringe Carton)

Simponi 50 mg/0.5 mL (golimumab) subcutaneous injection carton. It is labeled as a single-dose SmartJect autoinjector containing sterile solution. The packaging includes dosage and dispensing instructions, NDC 57894-070-02, and is manufactured by Janssen Biotech, Inc.*

FDA Label Image

Simponi 36

Simponi 100 mg/mL golimumab injection, solution in a single-dose prefilled syringe carton. The label highlights the prescription drug's strength and form, with instructions emphasizing subcutaneous injection and patient medication guide for pharmacists. Manufactured by Janssen Biotech, Inc.*

FDA Label Image

Simponi 37

The Simponi 100 mg/mL injection carton label shows branding with the Janssen Biotech, Inc. logo. It indicates Simponi (golimumab) as a subcutaneous injection solution supplied in a single-dose SmartJect autoinjector. The label includes the NDC 57894-071-02 and cautions for pharmacists to dispense the Medication Guide with the product.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.